Ciclesonide
Top View
- Spotlight on Fluticasone Furoate/Umeclidinium/ Vilanterol in COPD: Design, Development, and Potential Place in Therapy
- COVID-19 Ciclesonide Observational Study in Japan: Preliminary Report
- 2016-01686.Pdf
- Benefit Assessment of Medicinal Products with New Active
- Treatment of Asthma by the Inhaled Corticosteroid Ciclesonide Given Either in the Morning Or Evening
- Chronic Obstructive Pulmonary Disease (“COPD”) Medication Guide
- Drug Development for Asthma and COPD: a Regulatory Perspective
- The FDA-Approved Anti-Asthma Medicine Ciclesonide Inhibits Lung Cancer Stem Cells Through Hedgehog Signaling-Mediated SOX2 Regulation
- Therapeutic Interchange List
- Notice: Prescription Drug List (PDL): Fluticasone Propionate
- Newer and Common Inhaled Therapy Licensed for Asthma Or Copd February 2021
- Oral Steroid-Sparing Effect of High-Dose Inhaled Corticosteroids in Asthma
- Long-Acting Asthma and COPD Drugs Drug Effectiveness Review Project Summary Report
- Preferred Drug List (PDL)
- Customs Tariff - Schedule Xxi - 1
- Effects of Ciclesonide and Fluticasone on Cortisol Secretion in Patients with Persistent Asthma
- Triamcinolone Acetonide Clinical Pediatric Review
- Etats Rapides